Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

NCT02948777 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Evolocumab

Sponsor

Marja-Riitta Taskinen

Collaborators

[object Object]